Statistics
Publications
3
Citations
94
H-Index
3
Active since
2021
Sam Amaka is an author at Dana-Farber Cancer Institute specializing in cancer immunotherapy, immunology, and life sciences.
Publications per year
2021–2024
3
3
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Steven M. Horwitz, Ajit J. Nirmal, Jahan Rahman et al. · Nature Medicine · 2024 · 43 citations · Full text
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1
Wenchao Wu, Geoffrey M. Nelson, Raphael Koch et al. · Blood · 2021 · 36 citations · Full text
Life Sciences, Immunology, Oncology +10
1–3 of 3